Abeona Therapeutics Inc vs Visa Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Visa Inc trades at $362.12 (market cap $671.74B). The key difference: Visa Inc is far larger — about 1594.9× Abeona Therapeutics Inc's market cap, and Visa Inc pays a 0.74% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | V | |
|---|---|---|
Market Cap | $421.19M | $671.74B |
Sector | Health | Financials |
52-Week High | $7.45 | $370.47 |
52-Week Low | $4.17 | $295.52 |
Enterprise Value | $276.10M | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →